Showing results (241-250 of 283) with videos related to
Sort By:
Pageof 29
Journal for Immunotherapy of Cancer|September 12, 2022
Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activityOdd L Gammelgaard, Mikkel G Terp, Christian Renn, et al.Nature Communications|August 26, 2021
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancerCarla L Alves, Sidse Ehmsen, Mikkel G Terp, et al.Nature Communications|November 19, 2020
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapyYi Bao, Gokce Oguz, Wee Chyan Lee, et al.Science Translational Medicine|December 17, 2025
Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancerCarla L Alves, Leena Karimi, Mikkel G Terp, et al.International Journal of Cancer|August 11, 2024
Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancerCharlotte K Kindt, Carla L Alves, Sidse Ehmsen, et al.Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 19, 2015
Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathwaysStine Ninel Hansen, David Westergaard, Mathilde Borg Houlberg Thomsen, et al.Cancer Research|September 10, 2025
SWI/SNF Functions as a Gatekeeper of Enhancer Chromatin Access to Control Progression of Mesenchymal Triple-Negative Breast CancerRikkemaja Isahbell J Møldrup, Mikkel G Terp, Simon T Jakobsen, et al.Breast Cancer Research : BCR|February 19, 2021
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancerKamila Kaminska, Nina Akrap, Johan Staaf, et al.Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 25, 2013
TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expressionChristina Bjerre, Lena Vinther, Kirstine C Belling, et al.Hypertension (Dallas, Tex. : 1979)|September 9, 2022
Quantitative Phosphoproteomics of the Angiotensin AT2-Receptor Signaling Network Identifies HDAC1 (Histone-Deacetylase-1) and p53 as Mediators of Antiproliferation and ApoptosisA Augusto Peluso, Stefan J Kempf, Thiago Verano-Braga, et al.Pageof 29